CAPRCapricor Therapeutics, Inc.

1. Aug 24, 2026On August 24, 2026, Capricor Therapeutics, Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration (“FDA”) has extended the Prescription Drug User Fee Act (“PDUFA”) target action date for its Biologics License Application (“BLA”) for Deramiocel, an investigational cell therapy …Other event · Form 8-K
2. Aug 13, 2026Capricor Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update.Earnings release · press release
3. Jul 30, 2026On July 29, 2026, the U.S. Food and Drug Administration's ("FDA") Cellular, Tissue and Gene Therapies Advisory Committee voted that available evidence did not support the effectiveness of Deramiocel for the treatment of cardiomyopathy in patients with Duchenne muscular dystrophy (“DMD”), a rare and life-threatening …Other event · Form 8-K
4. Jul 29, 2026Phase 3 Peer-Review Publication; Update to Statistical Model for LVEF On July 29, 2026, Capricor Therapeutics, Inc. ("Capricor" or the "Company") issued a press release announcing the publication in The Lancet of the final one-year results from its HOPE-3, Phase 3 clinical trial evaluating Deramiocel, its …Other event · Form 8-K
5. Jul 14, 2026On July 9, 2026, Capricor Therapeutics, Inc. (“Capricor”) entered into a Lease Agreement (the “Lease”) with ARE-SD Region No. 39 Owner, LLC (“Landlord”) for approximately 171,000 rentable square feet located at 9625 Towne Centre Drive, San Diego, California, to be used as Capricor’s new headquarters, including …Material agreement entered · Form 8-K
6. Jun 26, 2026On June 26, 2026, Capricor Therapeutics, Inc. (the “Company” or “Capricor”) issued a press release announcing that the Cellular, Tissue, and Gene Therapies Advisory Committee of the U.S. Food and Drug Administration (“FDA”) is planning to convene an Advisory Committee meeting to discuss the Company's Biologics License …Other event · Form 8-K
7. May 12, 2026Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update.Earnings release · press release
8. May 7, 2026On May 7, 2026, Capricor announced that it has filed a Complaint for Equitable Relief and Application for Preliminary Injunction in the Superior Court of New Jersey, Chancery Division, Bergen County (the “Lawsuit”)Regulation FD disclosure · Form 8-K
9. Mar 12, 2026Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update.Earnings release · press release
10. Mar 10, 2026As disclosed above, the FDA has lifted the previously issued CRL and resumed review of the Company’s BLA seeking full approval of Deramiocel, an investigational cell therapy, for the treatment of DMD cardiomyopathy.Regulation FD disclosure · Form 8-K
11. Dec 5, 2025On December 5, 2025, Capricor Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an underwriting agreement (the “Underwriting Agreement”) with Piper Sandler & Co. and Oppenheimer & Co. Inc. as representatives of the underwriters (the “Underwriters”), pursuant to which the Company agreed to sell …Regulation FD disclosure · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.